View All Documents & Correspondence
Compositions And Methods For The Treatment Of Inflammatory Skin Diseases And Cancer
Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II formula III, formula IV, formula V, formula VI, formula VII, and formula VIII and the methods for the treatment of inflammatory skin diseases and cancer may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of facial hirsutism, GI Polyps, rosacea, acne, melanoma, psoriasis, dermatitis and cancer including gliomas, gastrointestinal polyps, anaplastic astrocytoma and metastatic cancers.
Notices, Deadlines & Correspondence
Patent Information
Applicants
CELLIX BIO PRIVATE LIMITED
Inventors
1. KANDULA, Mahesh
Specification
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202147000040-STATEMENT OF UNDERTAKING (FORM 3) [01-01-2021(online)].pdf | 2021-01-01 |
| 2 | 202147000040-PROOF OF RIGHT [01-01-2021(online)].pdf | 2021-01-01 |
| 3 | 202147000040-PRIORITY DOCUMENTS [01-01-2021(online)].pdf | 2021-01-01 |
| 4 | 202147000040-POWER OF AUTHORITY [01-01-2021(online)].pdf | 2021-01-01 |
| 5 | 202147000040-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105) [01-01-2021(online)].pdf | 2021-01-01 |
| 6 | 202147000040-FORM FOR SMALL ENTITY(FORM-28) [01-01-2021(online)].pdf | 2021-01-01 |
| 7 | 202147000040-FORM 1 [01-01-2021(online)].pdf | 2021-01-01 |
| 8 | 202147000040-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [01-01-2021(online)].pdf | 2021-01-01 |
| 9 | 202147000040-DRAWINGS [01-01-2021(online)].pdf | 2021-01-01 |
| 10 | 202147000040-DECLARATION OF INVENTORSHIP (FORM 5) [01-01-2021(online)].pdf | 2021-01-01 |
| 11 | 202147000040-COMPLETE SPECIFICATION [01-01-2021(online)].pdf | 2021-01-01 |
| 12 | 202147000040-Correspondence, Form-1 And POA_08-01-2021.pdf | 2021-01-08 |
| 13 | 202147000040-FORM 3 [03-07-2021(online)].pdf | 2021-07-03 |
| 14 | 202147000040.pdf | 2021-10-18 |
| 15 | 202147000040-FORM 3 [19-04-2022(online)].pdf | 2022-04-19 |
| 16 | 202147000040-FORM 18 [07-06-2022(online)].pdf | 2022-06-07 |
| 17 | 202147000040-FER.pdf | 2022-07-25 |
| 18 | 202147000040-RELEVANT DOCUMENTS [22-11-2022(online)].pdf | 2022-11-22 |
| 19 | 202147000040-POA [22-11-2022(online)].pdf | 2022-11-22 |
| 20 | 202147000040-FORM 13 [22-11-2022(online)].pdf | 2022-11-22 |
| 21 | 202147000040-FORM 3 [25-01-2023(online)].pdf | 2023-01-25 |
| 22 | 202147000040-FER_SER_REPLY [25-01-2023(online)].pdf | 2023-01-25 |
| 23 | 202147000040-DRAWING [25-01-2023(online)].pdf | 2023-01-25 |
| 24 | 202147000040-CORRESPONDENCE [25-01-2023(online)].pdf | 2023-01-25 |
| 25 | 202147000040-CLAIMS [25-01-2023(online)].pdf | 2023-01-25 |
| 26 | 202147000040-US(14)-HearingNotice-(HearingDate-10-01-2024).pdf | 2023-12-13 |
| 27 | 202147000040-Correspondence to notify the Controller [09-01-2024(online)].pdf | 2024-01-09 |
Search Strategy
| 1 | 202147000040searchE_22-07-2022.pdf |